Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.

Brisse HJ, Blanc T, Schleiermacher G, Mosseri V, Philippe-Chomette P, Janoueix-Lerosey I, Pierron G, Lapouble E, Peuchmaur M, Fréneaux P, Galmiche L, Algret N, Peycelon M, Michon J, Delattre O, Sarnacki S.

PLoS One. 2017 Sep 25;12(9):e0185190. doi: 10.1371/journal.pone.0185190. eCollection 2017.

2.

Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.

Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, Lapouble E, Bellini A, Clement N, Iacono I, Bréjon S, Carrere M, Reyes C, Hocking T, Bernard V, Peuchmaur M, Corradini N, Faure-Conter C, Coze C, Plantaz D, Defachelles AS, Thebaud E, Gambart M, Millot F, Valteau-Couanet D, Michon J, Puisieux A, Delattre O, Combaret V, Schleiermacher G.

Clin Cancer Res. 2016 Nov 15;22(22):5564-5573. doi: 10.1158/1078-0432.CCR-16-0500. Epub 2016 Jul 20.

3.

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, Díaz de Ståhl T, Hedborg F.

BMC Cancer. 2013 May 9;13:231. doi: 10.1186/1471-2407-13-231.

4.

Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.

Guimier A, Ferrand S, Pierron G, Couturier J, Janoueix-Lerosey I, Combaret V, Mosseri V, Thebaud E, Gambart M, Plantaz D, Marabelle A, Coze C, Rialland X, Fasola S, Lapouble E, Fréneaux P, Peuchmaur M, Michon J, Delattre O, Schleiermacher G.

PLoS One. 2014 Jul 11;9(7):e101990. doi: 10.1371/journal.pone.0101990. eCollection 2014.

5.

Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.

Souzaki R, Tajiri T, Teshiba R, Kinoshita Y, Yosue R, Kohashi K, Oda Y, Taguchi T.

J Pediatr Surg. 2011 Dec;46(12):2228-32. doi: 10.1016/j.jpedsurg.2011.09.005.

PMID:
22152855
6.

Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.

Irtan S, Brisse HJ, Minard-Colin V, Schleiermacher G, Galmiche-Rolland L, Le Cossec C, Elie C, Canale S, Michon J, Valteau-Couanet D, Sarnacki S.

Pediatr Blood Cancer. 2015 Sep;62(9):1543-9. doi: 10.1002/pbc.25511. Epub 2015 Mar 27.

PMID:
25820608
7.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

8.

FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.

Spitz R, Hero B, Ernestus K, Berthold F.

Med Pediatr Oncol. 2003 Jul;41(1):30-5.

PMID:
12764740
9.

Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.

Cao Y, Jin Y, Yu J, Wang J, Qiu Y, Duan X, Ye Y, Cheng Y, Dong L, Feng X, Wang D, Li Z, Tian X, Wang H, Yan J, Zhao Q.

Oncotarget. 2017 Jul 25;8(30):49689-49701. doi: 10.18632/oncotarget.17917.

10.

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.

Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4323-8. doi: 10.1073/pnas.0910684107. Epub 2010 Feb 9.

11.

[Genomic profile in high risk neuroblastoma by comparative genomic hybridization].

Noguera Salvá R, Piqueras Franco M, Ruiz Saurí A, Llombart-Bosch A, Castel Sánchez V, Navarro Fos S.

An Pediatr (Barc). 2006 May;64(5):449-56. Spanish.

12.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.

Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28.

13.

Accumulation of segmental alterations determines progression in neuroblastoma.

Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O.

J Clin Oncol. 2010 Jul 1;28(19):3122-30. doi: 10.1200/JCO.2009.26.7955. Epub 2010 Jun 1.

PMID:
20516441
14.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

15.

Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.

Spitz R, Hero B, Simon T, Berthold F.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3368-73.

16.

cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.

Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J.

BMC Genomics. 2004 Sep 20;5:70.

17.

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG.

J Clin Oncol. 2014 Oct 1;32(28):3169-76. doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25.

18.

Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.

Spitz R, Hero B, Ernestus K, Berthold F.

Clin Cancer Res. 2003 Jan;9(1):52-8.

19.

Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state.

Lundberg G, Jin Y, Sehic D, Øra I, Versteeg R, Gisselsson D.

PLoS One. 2013;8(3):e59268. doi: 10.1371/journal.pone.0059268. Epub 2013 Mar 21.

20.

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J, Sommelet D.

J Clin Oncol. 1997 Mar;15(3):1171-82.

PMID:
9060561

Supplemental Content

Support Center